Chong Kun Dang Pharmaceutical Full Year 2023 Earnings: EPS: ₩16,704 (vs ₩6,314 in FY 2022)

Chong Kun Dang Pharmaceutical (KRX:185750) Full Year 2023 Results

Key Financial Results

• Revenue: ₩1.67t (up 12% from FY 2022).
• Net income: ₩212.5b (up 163% from FY 2022).
• Profit margin: 13% (up from 5.4% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: ₩16,704 (up from ₩6,314 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chong Kun Dang Pharmaceutical Earnings Insights

Looking ahead, revenue is expected to decline by 1.3% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in South Korea are expected to grow by 14%.

Performance of the South Korean Pharmaceuticals industry.

The company's shares are up 3.5% from a week ago.

Valuation

It's possible that Chong Kun Dang Pharmaceutical could be undervalued with our 6-factor valuation analysis indicating a potential opportunity. Click here to view our comprehensive analysis and gain insights into the stock's investment prospects.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.